Henrik Zetterberg1, Tobias Skillbäck2, Niklas Mattsson3, John Q Trojanowski4, Erik Portelius2, Leslie M Shaw4, Michael W Weiner5, Kaj Blennow2. 1. Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, Mölndal, Sweden2Department of Molecular Neuroscience, University College London Institute of Neurology, London, Engla. 2. Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, Mölndal, Sweden. 3. Department of Veterans Affairs Medical Center, University of California, San Francisco4Center for Imaging of Neurodegenerative Diseases, University of California, San Francisco5Department of Radiology and Biomedical Imaging, University of California, San. 4. Department of Pathology and Laboratory Medicine, Center for Neurodegenerative Disease Research, Institute on Aging, University of Pennsylvania School of Medicine, Philadelphia. 5. Department of Veterans Affairs Medical Center, University of California, San Francisco.
Abstract
IMPORTANCE: The extent to which large-caliber axonal degeneration contributes to Alzheimer disease (AD) progression is unknown. Cerebrospinal fluid (CSF) neurofilament light (NFL) concentration is a general marker of damage to large-caliber myelinated axons. OBJECTIVE: To test whether CSF NFL concentration is associated with cognitive decline and imaging evidence of neurodegeneration and white matter change in AD. DESIGN, SETTING, AND PARTICIPANTS: A commercially available immunoassay was used to analyze CSF NFL concentration in a cohort of patients with AD (n = 95) or mild cognitive impairment (MCI) (n = 192) and in cognitively normal individuals (n = 110) from the Alzheimer's Disease Neuroimaging Initiative. The study dates were January 2005 to December 2007. The NFL analysis was performed in November 2014. MAIN OUTCOMES AND MEASURES: Correlation was investigated among baseline CSF NFL concentration and longitudinal cognitive impairment, white matter change, and regional brain atrophy within each diagnostic group. RESULTS: Cerebrospinal fluid NFL concentration (median [interquartile range]) was higher in the AD dementia group (1479 [1134-1842] pg/mL), stable MCI group (no progression to AD during follow-up; 1182 [923-1687] pg/mL), and progressive MCI group (MCI with progression to AD dementia during follow-up; 1336 [1061-1693] pg/mL) compared with control participants (1047 [809-1265] pg/mL) (P < .001 for all) and in the AD dementia group compared with the stable MCI group (P = .01). In the MCI group, a higher CSF NFL concentration was associated with faster brain atrophy over time as measured by changes in whole-brain volume (β = -4177, P = .003), ventricular volume (β = 1835, P < .001), and hippocampus volume (β = -54.22, P < .001); faster disease progression as reflected by decreased Mini-Mental State Examination scores (β = -1.077, P < .001) and increased Alzheimer Disease Assessment Scale cognitive subscale scores (β = 2.30, P < .001); and faster white matter intensity change (β = 598.7, P < .001). CONCLUSIONS AND RELEVANCE: Cerebrospinal fluid NFL concentration is increased by the early clinical stage of AD and is associated with cognitive deterioration and structural brain changes over time. This finding corroborates the contention that degeneration of large-caliber axons is an important feature of AD neurodegeneration.
IMPORTANCE: The extent to which large-caliber axonal degeneration contributes to Alzheimer disease (AD) progression is unknown. Cerebrospinal fluid (CSF) neurofilament light (NFL) concentration is a general marker of damage to large-caliber myelinated axons. OBJECTIVE: To test whether CSF NFL concentration is associated with cognitive decline and imaging evidence of neurodegeneration and white matter change in AD. DESIGN, SETTING, AND PARTICIPANTS: A commercially available immunoassay was used to analyze CSF NFL concentration in a cohort of patients with AD (n = 95) or mild cognitive impairment (MCI) (n = 192) and in cognitively normal individuals (n = 110) from the Alzheimer's Disease Neuroimaging Initiative. The study dates were January 2005 to December 2007. The NFL analysis was performed in November 2014. MAIN OUTCOMES AND MEASURES: Correlation was investigated among baseline CSF NFL concentration and longitudinal cognitive impairment, white matter change, and regional brain atrophy within each diagnostic group. RESULTS: Cerebrospinal fluid NFL concentration (median [interquartile range]) was higher in the AD dementia group (1479 [1134-1842] pg/mL), stable MCI group (no progression to AD during follow-up; 1182 [923-1687] pg/mL), and progressive MCI group (MCI with progression to AD dementia during follow-up; 1336 [1061-1693] pg/mL) compared with control participants (1047 [809-1265] pg/mL) (P < .001 for all) and in the AD dementia group compared with the stable MCI group (P = .01). In the MCI group, a higher CSF NFL concentration was associated with faster brain atrophy over time as measured by changes in whole-brain volume (β = -4177, P = .003), ventricular volume (β = 1835, P < .001), and hippocampus volume (β = -54.22, P < .001); faster disease progression as reflected by decreased Mini-Mental State Examination scores (β = -1.077, P < .001) and increased Alzheimer Disease Assessment Scale cognitive subscale scores (β = 2.30, P < .001); and faster white matter intensity change (β = 598.7, P < .001). CONCLUSIONS AND RELEVANCE: Cerebrospinal fluid NFL concentration is increased by the early clinical stage of AD and is associated with cognitive deterioration and structural brain changes over time. This finding corroborates the contention that degeneration of large-caliber axons is an important feature of AD neurodegeneration.
Authors: Bruce Fischl; David H Salat; Evelina Busa; Marilyn Albert; Megan Dieterich; Christian Haselgrove; Andre van der Kouwe; Ron Killiany; David Kennedy; Shuna Klaveness; Albert Montillo; Nikos Makris; Bruce Rosen; Anders M Dale Journal: Neuron Date: 2002-01-31 Impact factor: 17.173
Authors: Tobias Skillbäck; Bahman Farahmand; Jonathan W Bartlett; Christoffer Rosén; Niklas Mattsson; Katarina Nägga; Lena Kilander; Dorota Religa; Anders Wimo; Bengt Winblad; Lars Rosengren; Jonathan M Schott; Kaj Blennow; Maria Eriksdotter; Henrik Zetterberg Journal: Neurology Date: 2014-10-22 Impact factor: 9.910
Authors: Leslie M Shaw; Hugo Vanderstichele; Malgorzata Knapik-Czajka; Christopher M Clark; Paul S Aisen; Ronald C Petersen; Kaj Blennow; Holly Soares; Adam Simon; Piotr Lewczuk; Robert Dean; Eric Siemers; William Potter; Virginia M-Y Lee; John Q Trojanowski Journal: Ann Neurol Date: 2009-04 Impact factor: 10.422
Authors: Xue Hua; Alex D Leow; Suh Lee; Andrea D Klunder; Arthur W Toga; Natasha Lepore; Yi-Yu Chou; Caroline Brun; Ming-Chang Chiang; Marina Barysheva; Clifford R Jack; Matt A Bernstein; Paula J Britson; Chadwick P Ward; Jennifer L Whitwell; Bret Borowski; Adam S Fleisher; Nick C Fox; Richard G Boyes; Josephine Barnes; Danielle Harvey; John Kornak; Norbert Schuff; Lauren Boreta; Gene E Alexander; Michael W Weiner; Paul M Thompson Journal: Neuroimage Date: 2008-02-21 Impact factor: 6.556
Authors: André S L M Antunes; Valéria de Almeida; Fernanda Crunfli; Victor C Carregari; Daniel Martins-de-Souza Journal: Adv Exp Med Biol Date: 2021 Impact factor: 2.622
Authors: Georgette L Suidan; Pradeep K Singh; Sunita Patel-Hett; Zu-Lin Chen; Dmitri Volfson; Hitomi Yamamoto-Imoto; Erin H Norris; Robert D Bell; Sidney Strickland Journal: Blood Adv Date: 2018-05-08
Authors: David S Knopman; Samantha Budd Haeberlein; Maria C Carrillo; James A Hendrix; Geoff Kerchner; Richard Margolin; Paul Maruff; David S Miller; Gary Tong; Maria B Tome; Melissa E Murray; Peter T Nelson; Mary Sano; Niklas Mattsson; David L Sultzer; Thomas J Montine; Clifford R Jack; Hartmuth Kolb; Ronald C Petersen; Prashanthi Vemuri; Megan Zoschg Canniere; Julie A Schneider; Susan M Resnick; Gary Romano; Argonde Corien van Harten; David A Wolk; Lisa J Bain; Eric Siemers Journal: Alzheimers Dement Date: 2018-04 Impact factor: 21.566
Authors: Katherine A Gifford; Dandan Liu; Jacquelyn E Neal; Lealani Mae Y Acosta; Susan P Bell; Margaret E Wiggins; Kristi M Wisniewski; Mary Godfrey; Laura A Logan; Timothy J Hohman; Kimberly R Pechman; David J Libon; Kaj Blennow; Henrik Zetterberg; Angela L Jefferson Journal: Assessment Date: 2018-05-29
Authors: Elizabeth E Moore; Timothy J Hohman; Faizan S Badami; Kimberly R Pechman; Katie E Osborn; Lealani Mae Y Acosta; Susan P Bell; Michelle A Babicz; Katherine A Gifford; Adam W Anderson; Lee E Goldstein; Kaj Blennow; Henrik Zetterberg; Angela L Jefferson Journal: Neurobiol Aging Date: 2018-06-28 Impact factor: 4.673